Aspect Biosystems to Present at Cell & Gene Meeting on the Mediterranean 2019

Vancouver, BC, Canada - April 17, 2019 -  Aspect Biosystems has announced that Tamer Mohamed, chief executive officer, will present at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25, 2019 in Barcelona, Spain.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean will bring together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, the program will feature expert-led panels, extensive one-on-one partnering capabilities, and exclusive networking opportunities.

The meeting will feature presentations by 50+ leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as 35+ panelists and featured speakers.

The following are specific details regarding Aspect Biosystems’ presentation at the conference:

Event:          2019 Cell & Gene Meeting on the Mediterranean

Date:           Tuesday, April 23, 2019

Time:          11:15 AM

Location:     Gaudi Ballroom 2, Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, Spain

A live video webcast of all company presentations will be available at: http://www.meetingonthemed.com/webcast and will also be published on the conference website shortly after the event.

Please visit www.meetingonthemed.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Chelsey Hathaway at chathaway@alliancerm.org and interested media should contact Lyndsey Scull at lscull@alliancerm.org.

About Aspect Biosystems

Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company’s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living, human tissues for medical research, therapeutic discovery, and regenerative medicine products.

Contact

Natalie Korenic, Marketing & Communications Manager
Aspect Biosystems
604-263-0502
media@aspectbiosystems.com